← All trials
NCT01386827
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- Apr 1, 2011
- Completion date
- Apr 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of HelsinkiLead sponsor
- Swedish Institute for Infectious Disease ControlOverall official - principal investigator
- University of HelsinkiOverall official - principal investigator
- University of HelsinkiStudy director
- Karolinska InstituteStudy director
- Karolinska InstituteCollaborator
- University of HelsinkiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.